Hydroxychloroquine : interactions médicamenteuses

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid concomitant use of cimetidine 7.9 Rifampicin Lack of efficacy of hydroxychloroquine was reported when rifampicin was concomitantly administered. (notice Hydroxychloroquine, Interactions médicamenteuses)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (notice Emtricitabine, rilpivirine et ténofovir, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (notice Foscarnet, Interactions médicamenteuses)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (notice Fosfomycine, Interactions médicamenteuses)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (notice Ivabradine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (notice Lopinavir et ritonavir, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (notice Mirtazapine, Interactions médicamenteuses)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (notice Oxaliplatine, Interactions médicamenteuses)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. (notice Pénicillamine, Précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Drugs that Prolong the QT Interval : Avoid concomitant use. (notice Phénobarbital, Interactions médicamenteuses)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (notice Propafénone, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid the concomitant use of drugs known to prolong the QTc interval. (notice Sertraline, Interactions médicamenteuses)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (notice Vepdégestrant, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (notice Hydroxychloroquine, Mises en garde et précautions)

Some of the cases were associated with other risk factors for hepatic injury (e.g., alcohol use, concomitant hepatotoxic medications). (notice Hydroxychloroquine, Mises en garde et précautions)

Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (notice Hydroxychloroquine, Interactions médicamenteuses)

Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (notice Hydroxychloroquine, Interactions médicamenteuses)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (notice Arformotérol, Interactions médicamenteuses)

…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase… (notice Articaïne et adrénaline, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (notice Hydroxychloroquine, Interactions médicamenteuses)

• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Bupivacaïne, Interactions médicamenteuses)

• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Bupivacaïne et adrénaline, Interactions médicamenteuses)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (notice Buprénorphine, Mises en garde et précautions)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (notice Buprénorphine et naloxone, Mises en garde et précautions)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Chloroprocaïne, Précautions)

Cyclosporine An increased plasma cyclosporin level was reported when cyclosporin and PLAQUENIL were co-administered. (notice Hydroxychloroquine, Interactions médicamenteuses)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (notice Cinacalcet, Mises en garde et précautions)

Antimalarial : artemether/lumefantrine ↓ artemether ↓ dihydroartemisinin ↑ lumefantrine ↔ darunavir The combination of PREZISTA/ritonavir and artemether/lumefantrine can be used without dose adjustments. (notice Darunavir, Interactions médicamenteuses)

Antimalarial: artemether/lumefantrine artemether: effect unknown lumefantrine: effect unknown Monitor for a potential decrease of antimalarial efficacy or potential QT prolongation. (notice Darunavir et cobicistat, Interactions médicamenteuses)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Desflurane, Mises en garde et précautions)

Digoxin Concomitant PLAQUENIL and digoxin therapy may result in increased serum digoxin levels. (notice Hydroxychloroquine, Interactions médicamenteuses)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (notice Éfavirenz, Interactions médicamenteuses)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (notice Éfavirenz, lamivudine et ténofovir, Interactions médicamenteuses)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (notice Éribuline, Mises en garde et précautions)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (notice Étravirine, Interactions médicamenteuses)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (notice Fentanyl, Mises en garde et précautions)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (notice Formotérol, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Goséréline, Mises en garde et précautions)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (notice Héparine, Interactions médicamenteuses)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (notice Hydrocodone, Mises en garde et précautions)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Isoflurane, Mises en garde et précautions)

TYKERB may prolong the QT interval in some patients. (notice Lapatinib, Mises en garde et précautions)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Leuproréline, Mises en garde et précautions)

Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Lidocaïne et adrénaline, Interactions médicamenteuses)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Lidocaïne et prilocaïne, Interactions médicamenteuses)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (notice Lofexidine, Mises en garde et précautions)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Mépivacaïne, Interactions médicamenteuses)

Methotrexate Concomitant use of PLAQUENIL and methotrexate may increase the incidence of adverse reactions. (notice Hydroxychloroquine, Interactions médicamenteuses)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (notice Métronidazole, Interactions médicamenteuses)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (notice Mifépristone, Mises en garde et précautions)

Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (notice Hydroxychloroquine, Interactions médicamenteuses)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (notice Pasiréotide, Interactions médicamenteuses)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (notice Ponésimod, Interactions médicamenteuses)

Praziquantel Chloroquine has been reported to reduce the bioavailability of praziquantel. (notice Hydroxychloroquine, Interactions médicamenteuses)

…ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration… (notice Prilocaïne et adrénaline, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

…quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol… (notice Rifapentine, Interactions médicamenteuses)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (notice Rilpivirine, Mises en garde et précautions)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (notice Rocuronium, Mises en garde et précautions)

…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be… (notice Ropivacaïne, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (notice Sous-citrate de bismuth, métronidazole et tétracycline, Mises en garde et précautions)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Triptoréline, Mises en garde et précautions)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (notice Uméclidinium et vilantérol, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (notice Pilocarpine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (notice Hydroxychloroquine, Interactions médicamenteuses)